全球冠脉支架注册研究:一年结局与区域实践差异
1 年 TLF 为 3.2%,各区域从 2% 至 4.1% 不等,急性冠脉综合征患者出院时强效 P2Y12 抑制剂使用率 48%,1 年时 72% 使用任何双联抗血小板治疗,降脂治疗出院时 80.9%、1 年时 75.5%。
要点
- 1 年 TLF 为 3.2%,各区域在 2% 至 4.1% 之间
- ACS 患者出院时强效 P2Y12 抑制剂使用率仅 48%
- 降脂治疗出院时 80.9%、1 年时 75.5%,依从性欠佳
核心结论
- 全球代表性注册显示,使用新一代薄strut西罗莫司洗脱冠脉支架的当代 PCI 在跨临床表现和大陆间 1 年 TLF 较低。
- 抗血小板和降脂治疗的现行推荐依从性不理想。
研究设计与样本
- e-Ultimaster 为全comer、前瞻性、全球注册研究(NCT02188355),采用独立事件裁定,纳入接受研究支架 PCI 的患者。
主要发现
- 1 年 TLF 发生于 3.2% 的患者,范围从 2%(非洲/中东)至 4.1%(南美/墨西哥)。
- 急性冠脉综合征患者出院时强效 P2Y12 抑制剂处方率为 48%,1 年时 72% 使用任何双联抗血小板治疗。
- 降脂治疗在出院时和 1 年时分别用于 80.9% 和 75.5% 的患者。
- 报告了治疗患者特征及 PCI 实践的区域差异。
临床怎么用
- 使用该新一代薄strut西罗莫司洗脱冠脉支架行 PCI 的 1 年 TLF 发生率较低,可支持其全comer应用。
- 需关注并改进急性冠脉综合征患者出院时强效 P2Y12 抑制剂及降脂治疗的依从性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The primary objective was to assess the performance of a new generation thin-strut sirolimus-eluting coronary stent with abluminal biodegradable polymer in an all comer population. The secondary objective was to detail differences in contemporary percutaneous coronary intervention (PCI) practice worldwide. METHODS: e-Ultimaster was an all-comer, prospective, global registry (NCT02188355) with independent event adjudication enrolling patients undergoing PCI with the study stent. The primary outcome measure was target lesion failure (TLF) at 1 year, defined as the composite of cardiac death, target vessel myocardial infarction and clinically driven target lesion revascularisation. Data were stratified according to 4 geographical regions. RESULTS: A total of 37 198 patients were enrolled (Europe 69.2%, Asia 17.8%, Africa/Middle East 6.6% and South America/Mexico 6.5%) and 1-year follow-up was available for 35 389 patients (95.1%). One-year TLF occurred in 3.2% of the patients, ranging from 2% (Africa/Middle East) to 4.1% (South America/Mexico). In patients with acute coronary syndrome, potent P2Y12 inhibitors were prescribed in 48% of patients at discharge, while at 1 year 72% were on any dual antiplatelet therapy. Lipid-lowering treatment was administered in 80.9% and 75.5% of patients at discharge and 1 year, respectively. Regional differences in the profile of the treated patients as well as in PCI practice were reported. CONCLUSIONS: In this investigation with worldwide representation, contemporary PCI using a new generation thin-strut sirolimus-eluting coronary stent with abluminal biodegradable polymer was associated with low 1-year TLF across clinical presentations and continents. Suboptimal adherence to current recommendations around antiplatelet and lipid lowering treatments was detected.
引用
- Cimci M, Polad J, Mamas M, et al. Outcomes and regional differences in practice in a worldwide coronary stent registry. Heart. 2022. PMID: 35012960. doi:10.1136/heartjnl-2021-320116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。